Angiogenesis Modulations in Health and Disease, 2013 Practical Applications of Pro- and Anti-angiogenesis Targets

Preface.- Angiogenesis assays: an appraisal of current techniques.- Survey of pro-angiogenesis strategies.- Angiogenesis modulation by arachidonic acid – derived lipids: positive and negative regulators of angiogenesis.- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects.- Actions of steroids and peptide hormones on angiogenesis.- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.-  Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment.- Impact of nanotechnology on therapeutic angiogenesis.- Survey of anti-angiogenesis strategies.- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis.- Integrin antagonists and angiogenesis.- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology.- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration.- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit.- Biomarkers of response and resistance to anti-angiogenic treatment.- Speculations on new directions in which angiogenesis may proceed. Index.

In-depth explanations of pro-angiogenesis and anti-angiogenesis targets and their evaluation methods Clinical implications of pro-angiogenesis and anti-angiogenesis strategies Dedicated chapter on the impact of nanotechnology, stem cells, and biotechnology in angiogenesis control Detailed description of thyroid hormone analogues’ physiology and clinical potential Discussion of the future in the clinic for controlling angiogenesis